Akhu Licenses MC5R Blockers for Rapid-Acting Depression and Anxiety Medicine

Handshake
Akhu Therapeutics, Inc. Licensed MC5R Blockers from the University of Arizona and Texas A&M University

Akhu Therapeutics, Inc.  has acquired a license for key technology, MC5R blockers, to treat depression faster and more effectively than current therapies do. This exclusive, worldwide license was acquired from the University of Arizona and Texas A&M University. It also enables us to use this same technology to develop medicine to treat anxiety.

This technology involves an extensive series of state-of-the-art peptide compounds that are designed to block the melanocortin-5 receptor (MC5R). Therefore, it works differently than antidepressants (e.g., SSRIs) and anxiolytics (e.g., benzodiazepines). In our preclinical studies, this mechanism of action is more effective than those of antidepressants, and it and works in a fraction of the time. To view the full press release, (click here). To view an up-to-date list of media sites for the press release, (click here).

 

17 thoughts on “Akhu Licenses MC5R Blockers for Rapid-Acting Depression and Anxiety Medicine”

  1. Fine post. I learn something more ambitious on different sites everyday.
    It’ll constantly be stimulating to read content from other writers and practice a little something from their store.

    I’d favor to use some with the content on my blog whether you do’t mind.
    Natually I’ll give you a link on your internet blog.
    Thanks for sharing.

    Here is my blog; dungeon hunter 5 hack 2016

  2. I suffer from clinical depression that is resistant to Sri medication. Please keep me updated on any testing of mc5r products that you are working on.

Leave a Reply

Your email address will not be published. Required fields are marked *